



ConjuChem Biotechnologies Inc.
225, President-Kennedy Avenue
Third Floor, Suite 3950
Montréal, Québec H2X 3Y8
Canada

For immediate release

CONJUCHEM APPOINTS VICE PRESIDENT & GENERAL COUNSEL

- Ms. Jean Silveri to Assume Responsibilities Effective Immediately -

MONTREAL, September 4, 2007 – ConjuChem Biotechnologies Inc. (TSX:CJB) today announced the appointment of Ms. Jean Silveri as Vice President & General Counsel effective immediately. Ms. Silveri will be responsible for the ongoing development and execution of ConjuChem's legal and intellectual property strategies and contribute to the Company's overall strategic direction.

Ms. Silveri joins ConjuChem after nine years at Millennium Pharmaceuticals, Inc., where she most recently served as Associate General Counsel. In her tenure at Millennium, Ms. Silveri was responsible for advising the senior management team, business development group, and various commercial groups on matters related to intellectual property prosecution and litigation strategies, management of pharmaceutical partner relationships under Millennium's various collaboration agreements, product life cycle management strategies, and numerous product and company acquisition strategies. She was also responsible for creating the international intellectual property portfolio around the company's biologic clinical candidates.

Prior to joining Millennium, Ms. Silveri was an associate at the Boston law firm of Lahive & Cockfield where she specialized in the preparation, prosecution, and maintenance of international biotechnology patent portfolios and the preparation of legal opinions related to intellectual property rights. She received a B.A. in Biology from Assumption College, an M.A. in Cellular and Molecular Physiology from Harvard University, and a J.D. from Suffolk University Law School. She is admitted to practice in Massachusetts, the District of Columbia, and the United States Patent and Trademark Office.

About ConjuChem Biotechnologies

ConjuChem Biotechnologies, developer of next generation medicines from therapeutic peptides, is creating long-acting compounds based on bioconjugation platform technologies. When applied to peptides, the Company's systemic DAC[™] and PC-DAC[™] Technologies enable the creation of new drugs with significantly enhanced therapeutic properties as compared to the original peptide. Detailed descriptions of the Company can be viewed on the Company's website www.conjuchem.com.

Forward-Looking Statements

Some of the statements made herein may constitute forward-looking statements. These statements relate to future events or our future financial performance and involve known and unknown risks, uncertainties and other factors that may cause ConjuChem Biotechnologies' actual results, performance or achievements to be materially different from those expressed or implied by any of the Company's statements. Actual events or results may differ materially. We disclaim any intention, and assume no obligation, to update these forward-looking statements.

For more information, please contact:

Lennie Ryer, CA
Vice President, Finance & CFO
ConjuChem Biotechnologies Inc.
514-844-5558, ext. 224
ryer@conjuchem.com

James Smith
Investor Relations
416.815.0700, ext. 229
jsmith@equicomgroup.com